Asset comparator
Compare stocks, ETFs, indices, commodities, cryptocurrencies and bonds over the same period. Indicators that are not meaningful for a given asset type are flagged.
- Novartis
- Eurofins Scientific
累计表现对比（基数100）
每项资产在2025年10月13日时基数为100；数值120表示自该日起上涨20%（最近共同日期：2026年10月9日）。
Each performance is calculated in the asset's trading currency, without currency conversion.
指标
“不适用”表示该指标对此类资产没有意义：不应进行比较。
| 指标 | NovartisStock | Eurofins ScientificStock |
|---|---|---|
| 业绩与风险 | ||
| Performance over the periodChange in price between the first and last common dates. | +14.0% | +24.9% |
| Annualized performanceAverage annual return that would produce the same total performance. | +14.1% | +25.2% |
| Annualized volatilityTypical range of price movements: the higher it is, the more the price fluctuates. | 23.2% | 27.5% |
| Maximum DrawdownLargest decline from peak to subsequent trough over the period. | −15.0% | −21.3% |
| Sharpe RatioReturn achieved above the risk-free rate (5.24%), per unit of volatility. The higher it is, the better risk was rewarded over the period. | 0.52 | 0.91 |
| 1-day 95% Value at RiskOne-day loss that was exceeded in only 5% of cases (historical VaR). | −2.2% | −2.4% |
| 基本面 | ||
| Market capitalizationTotal market value of all shares (or circulating tokens for a crypto). | 226.38B CHF | 13.2B € |
| P/E (trailing 12 months)Share price divided by earnings per share: number of years of earnings paid. | 22.7 | 26.8 |
| Price-to-SalesMarket capitalization divided by annual revenue. | 4.0 | 1.8 |
| Net marginShare of revenue retained as profit. | 22.5% | 7.2% |
| Return on equityReturn on equity (ROE). | 30.3% | 11.3% |
| Revenue growthOver one year, latest published quarter compared with the same quarter of the previous year. | +0.8% | +2.5% |
| Dividend yieldAnnual dividend relative to the share price. | 3.14% | 0.95% |
| Debt / equityFinancial debt relative to shareholders' equity. | 117% | 96% |
期间相关性
取值范围为−1至1：接近1时，两类资产同涨同跌；接近0时，二者走势相互独立。
- Novartis / Eurofins Scientific0.18
对比分析
由人工智能生成的分析AI 仅根据上述数据比较所选资产，并指出哪些指标不可比。只有在您请求时才会生成文字内容。
以上信息仅供教育参考，不构成投资建议或个性化推荐。过往业绩不预示未来表现。